GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Median PS Value

Acorda Therapeutics (Acorda Therapeutics) Median PS Value

: $122.81 (As of Today)
View and export this data going back to 2006. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Acorda Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $95.081. Acorda Therapeutics's 10-Year median PS Ratio is 1.2916. Therefore, the Median PS Value for today is $122.81.

As of today (2024-04-19), Acorda Therapeutics's share price is $0.44. Acorda Therapeutics's Median PS Value is $122.81. Therefore, Acorda Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Acorda Therapeutics's Median PS Value or its related term are showing as below:

During the past 13 years, the highest Price to Median PS Value of Acorda Therapeutics was 0.83. The lowest was 0.07. And the median was 0.15.

ACORQ's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.77
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Acorda Therapeutics Median PS Value Historical Data

The historical data trend for Acorda Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,587.24 812.00 527.89 212.18 122.81

Acorda Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 212.18 172.95 135.64 120.54 122.81

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics Price-to-Median-PS-Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Price-to-Median-PS-Value falls into.



Acorda Therapeutics Median PS Value Calculation

Acorda Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=95.081*1.2916
=122.81

10-Year Median PS Ratio is 1.2916.
Acorda Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $95.081.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acorda Therapeutics  (OTCPK:ACORQ) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Acorda Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.44/122.81
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acorda Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (Acorda Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Executives
Thomas M. Burns director 2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen officer: CEO and President C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser officer: Chief Financial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff officer: General Counsel 11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem officer: Chief Commercial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales officer: Interim PAO & PFO 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman officer: Exec V Pres, Gen Cnsl & Sec C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: Exec. VP-Commercial Dvlpmnt C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence officer: Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank officer: Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc. 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123